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Gestational diabetes (GDM) results from failure of the
b cells to adapt to increased metabolic demands;
however, the cause of GDM and the extremely high
rate of progression to type 2 diabetes (T2D) remains
unknown. Using metabolomics, we show that the
furan fatty acid metabolite 3-carboxy-4-methyl-5-
propyl-2-furanpropanoic acid (CMPF) is elevated in
the plasma of humans with GDM, as well as impaired
glucose-tolerant and T2D patients. In mice, diabetic
levels of plasma CMPF induced glucose intoler-
ance, impaired glucose-stimulated insulin secretion,
and decreased glucose utilization. Mechanistically,
we show that CMPF acts directly on the b cell,
causing impaired mitochondrial function, decreasing
glucose-induced ATP accumulation, and inducing
oxidative stress, resulting in dysregulation of key
transcription factors and ultimately reduced insu-
lin biosynthesis. Importantly, specifically blocking
its transport through OAT3 or antioxidant treat-
ment could prevent CMPF-induced b cell dysfunc-
tion. Thus, CMPF provides a link between b cell
dysfunction and GDM/T2D that could be targeted
therapeutically.
INTRODUCTION
Gestational diabetes mellitus (GDM) currently afflicts 3%–14%
of pregnant women and is a condition where women with no
history of glucose intolerance transiently develop diabetes dur-
ing late pregnancy when there is significant insulin resistance
(Buchanan and Xiang, 2005). Acute complications of GDM
include fetal macrosomia leading to delivery complications, birth
injuries, congenital malformations, pre-eclampsia, and fetal hy-
poglycemia (Mitanchez, 2010). Longer term, mothers who had
GDM have an increased risk of metabolic syndrome, fatty liverCdisease, cardiovascular disease, and importantly, a very high
rate of progression to T2D with 25%–50% of women developing
T2D within 5 years postpartum (Bellamy et al., 2009; Kim et al.,
2002). Strong evidence is also emerging that fetal exposure to
the hyperinsulinemia and hyperglycemia associated with GDM
puts the child at a significantly increased risk of obesity, meta-
bolic syndrome, and T2D later in life (Reece, 2010). Although
there is general agreement that the significant decline in b cell
function is the cause of GDM, mechanistically it is not clear if it
is due to insufficient b cell mass and/or altered secretory dy-
namics (Buchanan and Xiang, 2005; Kim et al., 2010; Retnakaran
et al., 2010).
Many studies have associated glucolipotoxicity with b cell
dysfunction in T2D, suggesting that metabolites are likely caus-
ally related to diabetes development (Poitout et al., 2010). Dif-
ferential abundance of metabolites including free fatty acids
(FFAs) and amino acids are important diabetes markers, with
previous studies showing elevated levels of these analytes
in both GDM and T2D (Bjo¨rntorp et al., 1969; Boden, 2002,
2003; Bomba-Opon et al., 2006; Diaz et al., 2011). To date,
no study has effectively utilized metabolomic screening of
plasma to identify factors that cause GDM or induce progres-
sion from GDM to T2D. In the present study, we identified a
furan fatty acid metabolite, 3-carboxy-4-methyl-5-propyl-2-fur-
anpropanoic acid (CMPF), that is elevated in the plasma of
GDM, T2D, and prediabetic individuals compared to matched
controls with normal glucose tolerance (NGT). Under normal
fasting conditions, the circulating concentration of CMPF (20–
40 mM) (Sassa et al., 2000) is comparable to that of palmitate
(60 mM) (Quehenberger et al., 2010). Furan fatty acids are
incorporated into phospholipids and cholesterol esters (Spite-
ller, 2005) and are catabolized into dibasic urofuran acids,
including CMPF, which are excreted in the urine (Spiteller,
2005). Uremia, the only other condition where CMPF is known
to be elevated up to 370 mM (Niwa et al., 1988), is universally
associated with basal hyperinsulinemia and impaired first-
phase insulin secretion (Allegra et al., 1994; De Marchi et al.,
1987; DeFronzo, 1978; Nakamura et al., 1985). However,
CMPF has never been directly linked to glucose intolerance
or diabetes. Here we show that CMPF causes b cell dysfunctionell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc. 653
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patients through impairment of mitochondrial function and inhi-
bition of insulin biosynthesis.
RESULTS
Identification of Elevated CMPF in GDM and T2D
We used a mass spectrometry approach to examine 342 metab-
olites in fasting plasma samples from two cohorts of pregnant
women with or without GDM matched for age, race, family his-
tory of diabetes, and prepregnancy BMI (see Table S1 available
online) (Lawton et al., 2008). Women with GDM were found to
have a significantly altered metabolic profile compared to their
respective NGT controls, reflective of their diabetes (Butte,
2000) (Figures 1A and 1B). Similar to other studies in T2D popu-
lations, the most significant changes were observed in the levels
of FFAs (Bjo¨rntorp et al., 1969; Boden, 2002; Boden and Shul-
man, 2002; Bomba-Opon et al., 2006), primarily polyunsaturated
fatty acids (PUFAs) and long-chain fatty acids (Figures 1A and
1B). Interestingly, and unique to our study, the metabolite with
the largest fold change in our GDM population was a furan fatty
acid metabolite, CMPF (Figures 1B–1D). Elevation of CMPF in
GDM patients was independent of age, BMI, fasting blood
glucose, fasting plasma insulin, and triglyceride levels (Table
S2). An ELISA specific for CMPF quantified and validated the
elevated CMPF in the same cohort, showing a 7-fold upregula-
tion in GDM (Figure 1E). Intriguingly, in a subset of the same
women 1 year postpartum who had GDM and became impaired
glucose tolerant (IGT), CMPF was even more dramatically
elevated (12-fold) compared to women who were NGT at both
time points (Figure 1F). Therefore, CMPF is significantly upregu-
lated in GDMand subsequent IGT, suggesting it may be linked to
both GDM and the progression to T2D.
Due to the strong similarities between GDM and T2D, we
examined whether CMPF was also elevated in T2D relative to
NGT controls. Global metabolomics profiling on a cohort of
T2D patients compared to NGT controls revealed strong similar-
ities to the GDM population, including a significant elevation
in CMPF (Figure S1A; Table S3). In a distinct mixed cohort of
patients CMPF was significantly elevated to GDM-comparable
levels in T2D patients as compared to NGT controls (Figure 1G;
Table S4). The elevation of plasma CMPF in T2D patients was
independent of gender, age, BMI, and race (Figures 1H–1J and
S1B). However, levels of CMPF were significantly higher in
NGT males than in females (Figure 1H). Interestingly, treatment
with metformin, an antidiabetic medication that suppresses he-
patic triglyceride production (Viollet et al., 2012), had no effect
on plasma CMPF levels (Figure S1C).
CMPF Impairs Glucose Tolerance in Mice
To determine if CMPF has any relationship to glucose tolerance,
we performed a series of in vivo experiments in which plasma
CMPF was elevated to human diabetic levels. CMPF was in-
jected intomice intraperitoneally (i.p.) and plasma samples taken
at several time points. Plasma and tissue concentrations of
CMPF were quantified by ELISA as well as selected reaction
monitoring mass spectrometry (SRM-MS). Plasma concentra-
tions reached a maximum of 250 mM at 20 min postinjection
and remained elevated for at least 6 hr, ultimately returning to654 Cell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc.control levels within 24 hr (Figure 2A and S2A–S2C). At 2 hr post-
injection, CMPF was detected in metabolic tissues including
the kidney, liver, skeletal muscle, adipose, and pancreas (Fig-
ure S2B). Based on these kinetic studies, CMPF was injected
into mice i.p. for 7 days, followed by an oral glucose tolerance
test (OGTT). After 3 days of injections, there was no difference
in either fasting blood glucose or fasting plasma insulin levels
in CMPF-treated mice compared to vehicle-injected controls
(Figures 2B and 2C). However, after 7 days CMPF-treated
mice had both significantly higher fasting blood glucose and
plasma insulin levels (Figures 2D and 2E). OGTTs revealed
glucose intolerance in both 3- and 7-day CMPF-treated mice
(Figures 2B and 2D), and this corresponded to a significant inhi-
bition of glucose-stimulated insulin secretion (GSIS) with signifi-
cantly lower plasma insulin levels during glucose challenge
at both time points (Figures 2C and 2E). Therefore, elevated
plasma CMPF causes glucose intolerance and impaired insulin
secretion.
Interestingly, despite defective GSIS, 7-day CMPF treatment
was associated with fed-state hyperinsulinemia and hyperglu-
cagonemia (Figures 2F and S2D), prompting us to measure
insulin sensitivity. Despite elevated insulin levels, no significant
difference in insulin sensitivity was observed between CMPF
and vehicle-treated mice by insulin-tolerance testing (ipITT)
(Figure S2E). To more thoroughly examine integrated glucose
homeostasis, hyperinsulinemic euglycemic clamps were per-
formed. CMPF-treated mice required a significantly lower
glucose infusion rate compared to vehicle controls (Figure 2H),
which was attributed to a lower glucose appearance (Ra) rate in
the basal period and a lower glucose disappearance rate (Rd) in
the postinsulin clamp period (Figures 2I and 2J). This corre-
sponded to a lower glycolytic rate during both the pre- and
postinsulin clamp (Figure 2K). However, the whole-body insulin
response was not significantly different between CMPF-
and vehicle-treated mice, as there was no difference in the
incremental glucose turnover (postinsulin infusion/basal) (Fig-
ures 2L and S2F). Overall, this demonstrates that 7-day
CMPF treatment does not induce insulin resistance, but does
reduce glucose utilization, consistent with impaired glucose
tolerance.
CMPF Directly Impairs b Cell Function
The dysregulated insulin secretion observed in CMPF-treated
mice compelled us to examine b cell function. No difference in
insulin- or glucagon-positive area was observed by immunohis-
tochemical staining, suggesting that 7-day CMPF treatment did
not induce significant changes in b or a cell mass (Figures S3A–
S3D). There was also no significant difference in islet size be-
tween CMPF- and vehicle-treated mice (Figure 3A). However,
total insulin content from both isolated islets andwhole pancreas
was significantly reduced in CMPF-treated mice (Figures 3B
and 3C). Consistent with in vivo observations, islets isolated
from the 7-day CMPF-treated mice had significantly elevated
insulin secretion under substimulatory concentrations of glucose
(2.8 mM), and significantly lower insulin secretion under high-
glucose (16.7 mM) conditions (Figure 3D), corresponding to
a significantly decreased fold change in GSIS (Figure 3E).
Concurrently, high glucose failed to inhibit glucagon secretion
in isolated islets (Figure 3F).
Figure 1. CMPF Is Elevated in GDM and T2D Patients Compared to NGT Controls
(A) Differentially expressed metabolites in GDM patients compared to NGT controls categorized based on superpathway (n = 24, p < 0.05). (B) Relative abun-
dance of a subset of lipids with differential levels in GDMcompared to NGT controls (n = 12/group) based on global metabolomics. (C) Relative CMPF levels in two
independentmetabolomics screens on separate cohorts of GDMpatients (n = 12/group/cohort). (D) Chemical structure of CMPF. Levels of CMPF in the plasma of
patients with (E) GDM (n = 24), (F) IGT in the postpartum period (n = 5), and (G) T2D (n = 27–28) compared to NGT controls. Concentration of CMPF in NGT and T2D
patients classified based on (H) gender, (I) age, and (J) BMI. See also Figure S1 and Tables S1–S4 for patient information. Values are mean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001.
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Figure 2. CMPF Impairs Glucose Tolerance, GSIS, and Glucose Utilization in Mice
(A) CMPF concentration in mouse plasma following i.p. injection as measured by ELISA or selected reaction monitoring mass spectrometry (SRM-MS) using a
stable isotope labeled standard (n = 2–5). (B) Blood glucose and (C) corresponding plasma insulin levels during an OGTT after 3-day treatment with CMPF (n = 8).
(D) Blood glucose and (E) corresponding plasma insulin levels during an OGTT after 7-day treatment (n = 8). Fasting values inset for both (D) and (E). (F) Random-
fed plasma insulin on each day of injection, and (G) corresponding blood glucose (n = 8). (H) Glucose infusion rate, (I) glucose appearance and (J) disappearance
rates, (K) glycolytic rate, and (L) glucose turnaround rate (post/basal) during hyperinsulinemic euglycemic clamps on 7-day-treated mice (n = 4–5). See also
Figure S2. Values are mean ± SEM. *p < 0.05, ***p < 0.001.
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was due to a direct effect of CMPF on the b cells, a series of ex-
periments were performed on isolated human and mouse islets,
as well as a b cell line (MIN6). Initially, mouse islets were treated656 Cell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc.with varying doses of CMPF for 24 hr to determine if there was
any effect on GSIS. CMPF inhibited GSIS in a dose-dependent
manner, with a significant reduction in high glucose-stimulated
secretion after treatment with 150, 200, or 250 mM CMPF
Figure 3. CMPF Impairs GSIS and Decreases Insulin Content In Vivo
Islets isolated from 7-day-treatedmice were assessed for (A) islet size (n = 5–7 islets/mouse, 4mice) and (B) total insulin content (n = 4). (C) Total pancreatic insulin
content from 7-day-treatedmice (n = 3). (D) Glucose-stimulated insulin secretion (n = 8), (E) fold change in insulin secretion (high glucose over low glucose), and (F)
glucagon secretion (n = 4) in isolated islets from 7-day-treated mice. See also Figure S3. Values mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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compared to vehicle and 50 mM CMPF (comparable to NGT
circulating levels) (Figure 4A). Conjugation to varying concentra-
tions of BSA had no effect on 200 mMCMPF-mediated inhibition
of GSIS from mouse islets compared to BSA plus vehicle (Fig-
ure 4B). Islets and MIN6 cells were then treated for 4 or 24 hr
with vehicle control, 20 mM or 200 mM CMPF to correspond to
NGT and diabetic values, respectively. In both human and
mouse islets, 24 hr treatment with 200 mM CMPF significantly
decreased GSIS compared to both control and 20 mM CMPF
treatment conditions (Figures 4C and 4D). Mouse islets also
exhibited significantly increased insulin secretion under substi-
mulatory glucose concentrations (Figure 4C), consistent with
ex vivo findings (Figure 3D). Impaired GSIS was observed in
MIN6 cells treated for 4 hr (Figure 4E).
To determine the specificity of the effect of CMPF, mouse is-
lets were treated with varying doses of the fatty acid eicosapen-
taenoate (EPA), or the structurally related compound estrone
sulfate (ES). CMPF is produced through the metabolism of
furan fatty acids, which are produced from PUFAs (Batna
et al., 1993). The PUFA EPA was also shown to be significantly
elevated in both GDM and T2D plasma compared to NGT con-
trols (Figures 1B and S1A). However, treatment of islets with
NGT control (10 mM), diabetic (20 mM), or supraphysiologicalC(50 mM) concentrations of EPA for 24 hr had no effect on GSIS
(Figure S4A). Similarly, treatment of islets with either 10 mM
or 50 mM ES, both supraphysiological doses, had no effect
on GSIS (Figure S4B), suggesting that the effect of CMPF is
specific.
Decreased insulin secretion under high-glucose conditions
could be explained by fatty acid toxicity (Kharroubi et al.,
2004); however, mouse islets treated for 24 hr with vehicle con-
trol or 20 mMor 200 mMCMPF did not induce apoptosis or necro-
sis, either alone or in the presence of cytokines TNF-a, IF-g and
IL-1, or tunicamycin (2 ng/ml) (Figures 4F and S4C). In addition,
there was no indication of dedifferentiation, as there was no
difference in expression of Ngn3, Nanog, or Oct4, which have
previously been associated with a loss of b cell character (Fig-
ure S4D) (Talchai et al., 2012). In the absence of cell death or
dedifferentiation, CMPF could be impairing insulin secretion
by affecting insulin biosynthesis or its release. Consistent with
in vivo findings, total insulin content was significantly reduced
by treatment with 200 mM CMPF (Figure 4G). Total glucagon
content was not significantly changed (Figure 4H). Transmission
electron microscopy (TEM) was used to determine whether
CMPF was impairing insulin processing/packaging into gran-
ules. Mouse islets treated for 24 hr with 200 mM CMPF showed
normal granule morphology but had a dramatically decreasedell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc. 657
Figure 4. CMPF Impairs GSIS and Decreases Insulin Biosynthesis In Vitro
(A) Dose-response curve showing the effect of CMPF on GSIS (n = 3) and (B) the effect of 200 mMCMPF with varying concentrations of BSA (n = 3). GSIS from (C)
mouse islets (n = 16), (D) human islets (n = 10), and (E) MIN6 cells (n = 8) incubated for 24 hr with vehicle, 20 mM or 200 mM CMPF. (F) Percentage of annexin
V-positive mouse islet cells following 24 hr treatment (n = 3). (G) Total insulin (n = 8) and (H) glucagon (n = 5) content in 24 hr-treated islets. (I) Quantification of
dense core granule numbers in (J) TEM images of 24 hr-treated mouse islets (n = 4). White arrows indicate insulin granules. See also Figure S4. Values are mean ±
SEM. *p < 0.05, ***p < 0.001.
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and S4E).
CMPF Is Metabolized to Increase ROS
Lower total insulin content may be due to b cell exhaustion
caused by overstimulation and/or defective insulin production.
To determine the mechanism through which CMPF diminishes
insulin content, we measured insulin in the islet media following
24 hr treatment. There was no difference in accumulation of total
insulin (data not shown); however, there was substantially more
proinsulin in the media of CMPF-treated islets compared to con-
trols, consistent with an altered proinsulin:insulin ratio observed
in T2D patients (Kamoda et al., 2006) (Figure 5A). Impaired insulin
processing has previously been associated with elevations in ER
stress and/or reactive oxygen species (ROS) production (Wu and
Kaufman, 2006; Kashemsant and Chan, 2006). CMPF treatment
did not induce markers of ER stress including Chop, Bip, and
XBP-1 as examined by microarray and qPCR (Figures S5A and
S5B). We then examined whether CMPF was metabolized by b
cells, as excess substrate for the electron transport chain leads
to the formation of ROS (Joseph et al., 2004; Robson-Doucette
et al., 2011; Saadeh et al., 2012). CMPF was acutely added to
mouse islets and changes in mitochondrial membrane potential
(MMP) were measured. CMPF caused a transient membrane
hyperpolarization consistent with an increase in proton motive
force generated through b-oxidation (Figure 5B). This corre-
sponded to a 2-fold increase in ROS in CMPF-treated islets
over controls after 4 and 24 hr of treatment (Figure 5C). Increased
antioxidant gene expression, including uncoupling protein 2
(Ucp2) and catalase (Cat) after 24 hr of CMPF treatment sug-
gests that the cells are compensating for the oxidative stress
(Figures 5D and 5E) (Robson-Doucette et al., 2011). The increase
in ROS production caused by CMPF treatment was inhibited by
cotreatment with the antioxidant N-acetyl-cysteine (NAC) (Fig-
ure 5f). Importantly, CMPF had no effect on islets cotreated
with NAC (Figures 5G and 5H). Therefore, oxidative stress
caused by CMPF metabolism impairs GSIS and insulin process-
ing and is reversible through reducing ROS generation.
CMPF Impairs Insulin Biosynthesis
Elevated ROS has been shown to modulate insulin transcription
(Poitout and Robertson, 2008; Robertson, 2004) through alter-
ations in AKT and GSK3b activity (Boucher et al., 2006; Kawa-
mori et al., 2003, 2006; Ryu et al., 2011). To determine the
mechanism through which CMPF decreases insulin biosyn-
thesis, we examined its effect on these key regulators. Under
normal conditions, AKT and GSK3b have reciprocal activities.
Active pAKT phosphorylates and inactivates GSK3b, preventing
phosphorylation of downstream targets (Figure S5D) (Humphrey
et al., 2010). However, under conditions of oxidative stress, AKT
is inactive (Kawamori et al., 2006). Both AKT and GSK3b phos-
phorylation were significantly impaired after 24 hr CMPF treat-
ment compared to controls (Figures 5I and 5J), indicating
decreased AKT and increased GSK3b activity. We observed
no significant difference in either total ERK1/2 or pERK1/2
(Figure S5C) confirming specificity for the AKT pathway. To
determine if these changes had an effect on insulin transcription,
we examined the localization of two key insulin transcription
factors, PDX1 and FOXO1, using immunofluorescent staining.CFOXO1 is normally sequestered in the cytosol due to phosphor-
ylation by AKT (Kitamura et al., 2005). In CMPF-treated islets,
FOXO1 is translocated to the nucleus (Figures 5K and 5M),
reflecting decreased AKT activity (Kawamori et al., 2006).
Conversely, PDX1, which is directly phosphorylated by GSK3b
(Boucher et al., 2006), is sequestered outside of the nucleus,
consistent with increased GSK3b activity (Figures 5L and 5N).
Absolute levels of these transcription factors were not signifi-
cantly different, indicating that altered localization is not due to
changed protein abundance (Figure 5O). Translocation of both
FOXO1 and PDX1 was prevented by treatment with that antiox-
idant NAC, indicating that oxidative stress contributes to defec-
tive insulin biosynthesis (Figures 5K–5N). Altered activity of these
transcription factors was further confirmed by decreased mRNA
levels of key target genes including Ins1; transcription factors
Pdx1 and Mafa; proinsulin processing enzymes CpE, Pc1, and
Pc2; and the glucose transporter Glut2 (Boucher et al., 2006;
Kaneto et al., 2008) (Figure 6A).
CMPF Alters Glucose Metabolism
Given that CMPF causes hyperinsulinemia during the fed state
in vivo, and exaggerated secretion of insulin from islets under
nonstimulatory conditions in vitro, we rationalized that there
must be a defect in glucose sensing and/or secretion of insulin
that could not be solely explained by effects on insulin produc-
tion. Dispersed mouse islets treated for 24 hr with 200 mM
CMPF showed significantly greater hyperpolarization of the
MMP under substimulatory glucose concentrations, and signifi-
cantly reduced MMP hyperpolarization under high-glucose con-
ditions when compared to vehicle-treated controls (Figure 6B).
These data suggest that CMPF metabolism leads to excessive
protonmotive force resulting in increased insulin secretion under
low glucose conditions combined with impaired glucose meta-
bolism and thus reduced GSIS. Consistent with these findings,
CMPF increases basal and impairs high glucose-stimulated
ATP production in 24 hr CMPF-treated islets (Figure 6C). To
confirm changes in mitochondrial function, we analyzed 24 hr
200 mM CMPF-treated islets by microarray. Overall, 6.2% of
transcripts were significantly differentially expressed following
CMPF treatment. When organized based on biological process,
the largest differentially expressed cluster encompassed genes
involved in metabolism (38%) (Figure 6D). Specifically, we
observed a significant upregulation of genes related to fat
oxidation (Figure S6), which suggests a ‘‘switch’’ from glucose
oxidation-driven metabolism to fat oxidation (Elks, 1993). Such
a switch can decrease the b cell’s ability to sense andmetabolize
glucose (Hue and Taegtmeyer, 2009), limiting its capacity for
GSIS, and thus contributes to CMPF’s effect on b cells.
CMPF Enters the b Cell through OAT3
Dibasic urofuran acids, including CMPF, are normally secreted
in the urine (Deguchi et al., 2005), and CMPF is known to be
elevated in the plasma of uremic patients due to reduced expres-
sion of the organic anion transporters (OATs) which are respon-
sible for its clearance (Sassa et al., 2000). OAT3 (Slc22a8) and
OAT1 (Slc22a6) transport CMPF into the kidney proximal tubule
cells and require the cotransporter NaDC3 to function (Fig-
ure S7A) (Deguchi et al., 2004). OAT4 (Slc22a11) is an efflux
transporter that may remove CMPF from the proximal tubuleell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc. 659
Figure 5. CMPF Is Metabolized by b Cells, which Increases ROS Production and Reduces Insulin Biosynthesis
(A) Proinsulin in the media of 24 hr-treated islets (n = 4). (B) Mitochondrial membrane potential (MMP) in 2.8 mM glucose following acute addition of vehicle or
200 mM CMPF (n = 3). (C) ROS levels in 4 and 24 hr-treated mouse islets with representative images (n = 10–15 islets/mouse from 4 mice). (D) Expression of
antioxidant genes Cat and (E) Ucp2 (n = 4). (F) ROS accumulation in 24 hr-treated islets treated with 500 mMNAC (n = 10 islets/mouse from 4mice). (G) GSIS and
(H) total insulin content from 24 hr-treated islets cotreated with NAC (n = 4). Western blots showing (I) Ser9 phosphorylation of GSK3b, and (J) Ser473 phos-
phorylation of AKT (n = 3). (K) Immunofluorescent staining showing nuclear translocation of FOXO1 and (L) PDX1 after CMPF and NAC treatment (n = 3–6).
Quantification of nuclear percentage of (M) FOXO1 and (N) PDX1 based on immunofluorescent staining with CMPF and NAC treatment. (O) Western blots
showing protein abundance of PDX1 and FOXO1. See also Figure S5. Values are mean ± SEM. *p < 0.05, ***p < 0.001.
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Figure 6. CMPF Causes Decreased Expression of Insulin Biosynthesis Genes and Alters Metabolic Pathway Genes
(A) Expression of insulin, insulin processing enzymes, insulin transcription factors, and glucose-sensing genes in 24 hr-treated mouse islets (n = 5–6). (B)
Mitochondrial membrane potential (MMP) following 24 hr incubation, and change in fluorescence (n = 4). (C) Intracellular ATP content in islets treated for 24 hr with
vehicle control, 200 mM CMPF or 400 mM palmitate. (D) Classification of significantly changed genes by microarray in 24 hr-treated mouse islets based on
biological function (n = 3, p < 0.05). See also Figure S6. Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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et al., 2002). We therefore investigated whether CMPF also
enters the b cell through these transporters. Microarray analysis
of human islets showed expression of all four transcripts at levels
comparable to that of the b cell KATP channel Kcnj11 (Figure 7A).
This was further validated by quantitative PCR (Figure 7B)
and immunoblotting (Figure 7C) in human islets. To determine
protein localization, we performed immunofluorescent staining
in dispersed human islet cells (Figure 7D). OAT3 and NaDC3
show strong staining in insulin-positive b cells. OAT1 and
OAT4 are predominantly expressed in insulin-negative cells.
Costaining with glucagon revealed that OAT4 was also notCexpressed in glucagon-positive cells (Figure S7B). Therefore,
the OAT transporters are expressed in the islet, with the influx
transporters OAT3 and NaDC3 being strongly expressed in insu-
lin-positive cells.
To determine if OATs are responsible for CMPF transport into
b cells, we utilized inhibitors of OAT function. Probenecid is a
nonspecific OAT blocker (Miyamoto et al., 2012). Treatment of
murine islets with 1 mM probenecid for 24 hr rescued insulin
secretion from CMPF-treated islets to control levels (Figure 7E).
Importantly, probenecid was unable to rescue palmitate-
induced impairment of GSIS (Figure S7C), supporting the impor-
tance of CMPF transport in mediating the effect on GSIS, as wellell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc. 661
Figure 7. CMPF Enters the b Cell through Organic Anion Transporter 3
(A) Microarray analysis of human islets showing expression of OAT transporters and b cell genes (n = 3). Validation of OAT expression in human islets by (B) qPCR,
(C) western blot, and (D) immunofluorescent staining with insulin (n = 3–5). GSIS from murine islets cotreated with OAT inhibitors (E) Probenecid, (F) benzyl-
penicillin (PCG), and (G) p-aminohippurate (PAH) (n = 4). (H) Total insulin content frommurine islets cotreated with CMPF and PCG (n = 4). Validation of knockout
of OAT3 in OAT3KO islets compared to wild-type C57Bl/6 controls by (I) qPCR (n = 4) and (J) western blot (n = 3). (K) GSIS and (L) total insulin content from control
and OAT3KO islets treated for 24 hr with vehicle control or 200 mM CMPF (n = 5). See also Figure S7. Values mean ± SEM. *p < 0.05.
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vent other FFA-induced defects in GSIS. To determine which
OAT is primarily responsible for CMPF transport into b cells,
we treated islets with 300 mM of benzylpenicillin (PCG), an
OAT3-specific inhibitor, or 50 mM of p-aminohippurate (PAH),
an OAT1-specific inhibitor (Deguchi et al., 2005). Consistent
with previous reports that OAT3 is the dominant CMPF trans-
porter (Deguchi et al., 2005), PCG was able to rescue insulin
secretion and insulin content fromCMPF-treated islets to control
levels (Figures 7F and 7H). However, treatment with PAH had no
effect on secretion (Figure 7G). To further support this observa-
tion, islets were isolated from whole-body OAT3 knockout mice
(OAT3KO). Deletion of OAT3 from the islets was confirmed by
qPCR and western blot as compared to wild-type controls (Fig-
ures 7I and 7J). Importantly, treatment of OAT3KO islets with
200 mM CMPF for 24 hr had no effect on GSIS or insulin content
(Figures 7K and 7L). Therefore, CMPF is transported into the b
cell through OAT3, and blockage of this transporter prevents
CMPF from impairing GSIS and insulin biosynthesis.
DISCUSSION
The underlying cause of both GDM and T2D is a failure of the
b cell to respond to changing metabolic demands, namely
increased insulin resistance (Buchanan, 2001; Kahn, 2003; Pren-
tki and Nolan, 2006). Here we demonstrate that the furan fatty
acid metabolite CMPF impairs pancreatic b cell function at con-
centrations observed in patients with GDM, T2D, and IGT, corre-
lating with a progressive decline in b cell function during this
period (Retnakaran et al., 2010). Treatment with CMPF recapitu-
lates many key characteristics of diabetes, including basal
hyperinsulinemia (Wijendran et al., 1999) with impaired GSIS
and reduced whole-body glucose utilization (Bowes et al.,
1996; Ku¨hl, 1991). Interestingly, uremia in both humans and
rodent models is associated with elevated plasma CMPF (200–
400 mM; Niwa et al., 1988), as well as basal hyperglycemia
and hyperinsulinemia combined with impaired first-phase insulin
secretion, consistent with our in vivo observations (Allegra et al.,
1994; De Marchi et al., 1987; DeFronzo, 1978; Nakamura et al.,
1985). In vitro, we demonstrate that CMPF metabolism causes
b cell dysfunction through impairment of mitochondrial function
and decreased ATP synthesis, as well as inducing oxidative
stress. Elevated ROS levels altered the activity of key kinases
AKT and GSK3b (Kawamori et al., 2006), changing transcrip-
tional activity, and ultimately reduced insulin transcription
and posttranslational processing. Therefore, elevated plasma
CMPF may play an important causal role in b cell dysfunction
associated with GDM, T2D, and the progression from GDM
to T2D.
The effect of CMPF can be rescued by two distinct ap-
proaches: blocking CMPF entry into the b cell and reducing
ROS accumulation. Here we show that CMPF enters the b cell
through the OAT3 transporter, which has previously only been
functionally characterized on the basolateral membrane of kid-
ney proximal tubules cells (Deguchi et al., 2005), with low levels
of expression reported in the liver and brain (Deguchi et al., 2006;
Sweet et al., 2002). We show that CMPF transport can be
blocked through genetic deletion of OAT3, or by using the
commonly prescribed drugs probenecid, a ubiquitous OAT in-Chibitor, and benzylpenicillin, a specific inhibitor of OAT3 trans-
port. Interestingly, we show that while human b cells express
influx transporter OAT3, efflux transporter OAT4 is absent.
Thus during diabetes when plasma CMPF is elevated it can pre-
sumably enter the b cell but not exit, promoting its metabolism
and associated effects. Therefore, preventing CMPF influx and
increasing CMPF efflux from the b cell are attractive avenues
for future research into the prevention of b cell failure.
Once inside the b cell, CMPF is metabolized, causing impaired
glucose utilization and increased ROS production. Low-level
ROS potentiates GSIS, aiding the b cell in responding to acute
increases in nutrients including FFAs (Poitout and Robertson,
2008; Robson-Doucette et al., 2011; Saadeh et al., 2012). How-
ever, longer term, the b cell is particularly vulnerable to oxidative
stress due to relatively low expression of antioxidant enzymes
relative to other tissue types (Robertson, 2004). Treatment with
antioxidants has been proposed as an approach for the treat-
ment of T2D, and has been shown to attenuate islet fibrosis
and apoptosis and improve glucose tolerance and insulin
sensitivity in rodent models (Lee et al., 2011). Our finding that
pretreatment with the antioxidant NAC prevents CMPF from
inducing b cell failure suggests that antioxidant treatment may
also be used in the prevention and/or treatment of GDM.
EXPERIMENTAL PROCEDURES
Identification and Quantification of CMPF
Fasting plasma sampleswere collected fromwomen at 24–28weeks gestation
at the time of diagnosis to minimize differences in diet and medications that
may be associated with diabetes management. Glucose tolerance was tested
first using a glucose challenge test, followed by a 3 hr 100 g glucose OGTT.
Samples were tested using selected reaction monitoring mass spectroscopy
(SRM-MS) in combination with either gas chromatography (GC) or liquid chro-
matography (LC) for separation of the analytes comparing GDM and NGT pa-
tients (performed by Metabolon Inc.) as previously described (Allister et al.,
2013). Two independent cohorts with 12 samples/group/cohort were investi-
gated, and 342 biochemicals were quantified in each sample. A low q value
(<0.1) was used to determine confidence in results. Patients were matched
for age, race, BMI, and family history of diabetes. Plasma and tissue CMPF
levels were quantitatively determined by competitive enzyme-linked immuno-
sorbant assay (ELISA) or SRM-MS. The ELISA was performed following man-
ufacturer’s instructions (NovaTein Biologicals, USA) and detects total CMPF.
SRM-MS was performed by the Analytical Facility for Bioactive Molecules of
The Centre for the Study of Complex Childhood Diseases, The Hospital for
Sick Children, Toronto, Canada. SRM-MS protocol is described in Supple-
mental Information. Plasma samples from a subset of the same women
used for the GDM/NGT studies were taken 1 year postpartum for analysis
(five per group). Women with IGT had GDM during pregnancy, and NGT pa-
tients remained NGT at both time points. All women provided written informed
consent for their participation, and the protocol was approved by the Mount
Sinai Hospital Research Ethics Board.
CMPF Preparation
CMPF was purchased from Cayman Chemical (product number 10007133)
and dissolved in 100% ethanol to stock concentrations of 200 mM and
20 mM. CMPF was stored at 20C.
Intraperitoneal Injection of CMPF and Tolerance Tests
Micewere injected i.p.with6mg/kgCMPForvehicle control at 24hr intervals for
7 days and assessed for body weight, blood glucose, and plasma insulin
immediately prior to each injection. Tolerance test protocols can be found in
Supplemental Information. All experiments were approved by the Animal Care
Committee (University of Toronto or York University, where applicable) and
animals handled according to the Canadian Council of Animal Care guidelines.ell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc. 663
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Hyperinsulinemic euglycemic clamps were performed as previously described
(Liu et al., 2012) following 7 days of i.p. injections with CMPF or vehicle. Internal
and external cannulation was performed on day 3 of the injection protocol.
Immunohistochemistry and Islet Morphology
Protocol for immunohistochemistry can be found in Supplemental Information.
Human Islets
Human islets from review board-approved healthy donors were provided by
the IsletCore and Clinical Islet Laboratory (University of Alberta, Canada).
Islets were picked into low glucose DMEM media (GIBCO, reference number
11885-084) with 10% FBS 1% penicillin/streptomyosin, 1% L-glutamine,
and cultured overnight before use.
Glucose-Stimulated Insulin Secretion
GSIS protocols can be found in Supplemental Information.
Apoptosis and Necrosis
Dispersed isolated islets were treated for 24 or 48 hr with vehicle or CMPF.
Treatment was washed away before staining with Annexin V (0.5 mg/ml), pro-
pidium iodide (2 mg/ml), and Hoechst (2 mM) for 20 min at 37C. Images were
acquired and analyzed on a Thermo Fisher Cellomics ArrayScan VTI HCS
Reader using iDEV software. The filter settings for each dye were BGRFR
485-20 for Annexin V, BGRFR 549-15 for PI, and BGRFR 386-23 for Hoechst.
Cleaved caspase-3/7 assay was performed according to the manufacturer’s
instructions using ten islets treated for 24 hr (G8091, Promega, USA).
Gene Expression
Microarray and qPCR protocols can be found in Supplemental Information.
Transmission Electron Microscopy
Isolated islets were treated with either vehicle or 200 mMCMPF for 24 hr, fixed,
and images acquired as previously described (Basford et al., 2012). Granule
number was manually quantified using ImageJ software (Lu et al., 2010).
ROS Accumulation and Islet Size in Isolated Islets
The level of H2O2was determined using 2
0,70-dichlorodihydro fluorescein diac-
etate (CM-H2-DCFDA) (Molecular Probes, Invitrogen, Canada) as previously
described (Robson-Doucette et al., 2011) in isolated islets treated with either
vehicle or 200 mMCMPF for 4 or 24 hr. Bright-field images were used to deter-
mine islet size.
Mitochondrial Membrane Potential
Isolated dispersed islets were treated with either vehicle or 200 mM CMPF for
24 hr prior to loading with rhodamine 123 (25 ug/ml, 10 min) in 2.8 mM glucose
imaging buffer. NaN3 (5 mM) was added to fully depolarize the MMP (Diao
et al., 2008).
Western Blotting
Western blotting methodologies can be found in Supplemental Information.
Immunofluorescent Staining
The cellular localization of FOXO1 and PDX1was determined in dispersedCD1
mouse islet cells using immunofluorescence. The presence and localization of
the OATs was determined in dispersed human islet cells. Antibodies used are
detailed in Table S6. Staining was performed as previously described (Diao
et al., 2008). Images were acquired using a confocal microscope (Quorum
Wave FX Spinning Disc; PerkinElmer) and Volocity software (PerkinElmer). Co-
localization with Hoescht nuclear stain was determined with Volocity software.
Pharmacological Inhibition of OATs
Islets were treated with OAT inhibtors for 24 hr with or without 200 mM CMPF.
Probenecid (P36400, Invitrogen), PCG (13752, Sigma Aldrich), and PAH
(A3759, Sigma Aldrich) were dissolved in ultrapure water. ES (E0251, Sigma
Aldrich) was dissolved in 100% methanol. Palmitate was conjugated to BSA
prior to treatment of islets at a final concentration of 0.4 mM. In all cases, treat-
ments were compared to vehicle control.664 Cell Metabolism 19, 653–666, April 1, 2014 ª2014 Elsevier Inc.ATP Measurements
Isolated islets were equilibrated in 2 mM glucose KRB for 1 hr prior to stimu-
lation with 1 mM or 20 mM glucose for 5 min. Islets were then treated with
100 ml of 13 ATP extraction buffer from the StayBrite Highly Stable ATP Biolu-
minescence Assay Kit (Biovision) and homogenized. Homogenate was spun at
10,000 rpm for 2 min and supernatant was collected for ATP measurements
following manufacturer’s protocol.
Type 2 Diabetic Plasma
T2D and NGT control samples were collected frommixed-gender, mixed-race
patients. Samples used for global metabolomic profiling were obtained at 6th
People’s Hospital in Shanghai, China. For ELISA quantification, a subset of
samples were purchased from Bioreclamation Inc. Remaining samples were
obtained from the MRI Biorepository (IRB# 1011004282 [04-093]), by Eli Lilly
(Indianapolis).
Statistics
Statistical significance was assessed using either the Student’s t test, Welsh
t test, or a two-way ANOVA for repeated measures followed by a Bonferroni
post-test comparison where required. p < 0.05 was considered significant.
All data are mean ± SEM unless otherwise specified.
ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE55028. Human microarray data used in this study were obtained from
GSE40709.
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